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Abstract
Purpose of Review Rheumatoid arthritis (RA) is no longer considered a fixed phenotype but rather a disease continuum. This
review outlines the current and potential value of applying ultrasound (US) along this continuum: from the prediction of
progression to RA in at-risk individuals, to confirmation of the early diagnosis of RA, as well as the consideration of differential
diagnoses, and the use in disease monitoring and defining remission.
Recent Findings In individuals at-risk of RA (i.e., positive autoantibodies with symptoms but without synovitis), US has shown a
promising predictive value for the development of clinical arthritis, providing the opportunity to improve risk stratification (and
disease prevention) of these individuals. The detection of inflammation on US in patients with early undifferentiated arthritis, in
which a definite diagnosis cannot be reached, could predict evolution to persistent arthritis, mostly RA. This, in addition to the US
potential ability to identify disease specific patterns for different rheumatic conditions, might facilitate early diagnosis and, therefore,
improve the management of patients with RA, or other types of inflammatory arthritides. US has also demonstrated the capability to
predict radiographic progression, and relapse risk after treatment discontinuation, in RA patients in remission according to the
clinical instruments, raising implications in the management, including therapy discontinuation, of these patients.
Summary US has an undeniable value in the management of patients at different stages along the RA continuum. Further
research is needed to identify which groups of patients benefit the most from US imaging.
Keywords Musculoskeletal ultrasound . Rheumatoid arthritis . Differential diagnosis . Diseasemonitoring . Remission
Introduction
Ultrasound in Rheumatoid Arthritis
In 1997, at the American College of Rheumatology (ACR) pre-
course conference, an eminent musculoskeletal radiologist
discussed the role of imaging techniques for musculoskeletal
diseases. One of the questions asked at the end was ‘What about
ultrasound, you didn’t mention it?’ The answer was ‘Well, it is
only really useful for Baker’s cysts!’ Coincidently, that year saw
the first international trial of Remicade (infliximab) in rheuma-
toid arthritis (RA), the beginning of the concept of early diagno-
sis and ‘window of opportunity’, and the launch of a new wave
of ultrasound (US) machines which were better adapted for the
assessment of musculoskeletal diseases. From this point, there
began an increasing rise in the use of musculoskeletal US in
rheumatology practice, facilitated through a coordinated ap-
proach of education led by the European League Against
Rheumatology (EULAR) and the ACR, as well as other national
societies [1]. Some countries were swift to embrace the US
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concept and incorporate it into their educational programmes for
new trainees, whilst others have been more cautious, adopting a
more ‘wait and watch’, evidence-based approach. Without
doubt, the availability of US to rheumatologists was initially
met with much anticipation as it provided a direct way of im-
proving the accuracy of physical examination, enabling a deeper
understanding of joint pathophysiology, as well as providing a
means of guiding needles for interventions. As it was a technique
that rheumatologists could potentially perform themselves, it
could also enable immediate decision-making and therefore im-
prove efficiency. Over time, falling costs, the development of
educational opportunities, and increased credibility as a conse-
quence of expanding experience and evidence base have further
facilitated its uptake.
US images from 20 years ago are barely recognizable when
compared to those of today. Improvements in image resolu-
tion through the greater processing capabilities of computers
and the development of higher-frequency transducers
employing more sensitive Doppler modalities now enable
the depiction of tiny anatomical details (< 0.1 mm resolution)
and blood flow. Like with US, much excitement was initially
also directed at other advanced imaging techniques, such as
magnetic resonance imaging (MRI) and computed tomogra-
phy (CT) for early disease detection. MRI theoretically ap-
peared the perfect tool allowing simultaneous tomographic
imaging of bone and soft tissue. However, despite more recent
exploration into whole body MRI techniques, MRI has never
gained universal acceptance as a routine imaging technique
for RA, largely due to the feasibility aspects, such as availabil-
ity, cost, and patient tolerance. Many would argue that MRI
therefore remains a second/third line imaging tool (after X-ray
and US) for equivocal or uncertain cases and second line in
axial scanning (after X-ray). In contrast, CT is hampered by its
inability to image soft tissue and need for ionizing radiation
although it is arguably the best at depicting bone integrity.
In the context of RA, US is able to detect the signs of acute
inflammation, such as synovial and tenosynovial effusion
(Fig. 1), synovial hypertrophy, power Doppler (PD) signal, or
soft tissue oedema, as well as structural damage including bone
erosions (Fig. 2), loss of cartilage, or tendon tears [2, 3••].
US offers the opportunity to compare in ‘real-time’ the
anatomical findings with clinical assessment. In the evaluation
of patients with regional pain, the integration of the US infor-
mation with the clinical data yields obvious advantages to the
rheumatologist.
This review will highlight how the concept of RA has re-
cently changed in that it should no longer be considered as a
fixed phenotype, but one that evolves through different stages
of a continuum [4]. The potential utility of US in the manage-
ment of patients at different stages of this continuum (Fig. 3)
will be discussed: predicting progression to RA in at-risk in-
dividuals, early diagnosis of RA, differential diagnosis, mon-
itoring, and remission. The authors will attempt to provide a
balanced argument of the use of US although their disclosure
is that they all use US in their daily clinical practice and are
involved in research.
The Utility of Ultrasound in Managing Individuals at-
Risk of Rheumatoid Arthritis without Clinical Synovitis
A major recent advance in rheumatology has been the better
understanding of the preclinical phase of RA (‘pre-RA’). This
refers to patients who are considered ‘at-risk’ of developing
RA but as yet have not developed clinical synovitis or at least
enough synovitis to be confident of the diagnosis. In the liter-
ature, ‘at-risk’ particularly refers to those patients who have
positive autoantibodies with symptoms, such as fatigue and
‘clinically suspect arthralgia’ (CSA) but without signs of clin-
ically detectable inflammation. The potential to identify pa-
tients ‘at-risk’ for the future development of RA raises the
opportunity to prevent disease progression in these individuals
[5]. Many patients will have underlying genetic and environ-
mental predispositions (e.g., an affected first-degree relative
and/or cigarette smoking) although this is not necessarily the
case. Individuals with autoantibodies and symptoms but no
clinical synovitis are currently being followed within ‘at-risk’
cohorts [6, 7] but on an individual basis we need to know
which ones will develop clinical synovitis. In the absence of
any guidelines, management of these symptomatic at-risk pa-
tients is challenging and consequently current practice is
Fig. 1 Tenosynovitis of the third
flexor digitorum tendons in a
patient with rheumatoid arthritis.
The longitudinal scan of the
flexor digitorum tendons shows
the presence of synovial
hypertrophy (asterisks) and
synovial effusion (rounded dots)
in the synovial tendon sheath.
Legend: fdt, flexor digitorum
tendons
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highly variable [8]. Both over-treatment and under-treatment
will therefore naturally ensue, according to the clinical intui-
tion of the rheumatologist.
In recent years, as the concept of ‘at-risk of RA’ has
evolved, biomarkers such as US have been investigated to
address two broad areas. First, to improve our understanding
of disease pathogenesis, and second, for risk prediction and
stratification for intervention. Most rheumatology textbooks
inform us that RA is a synovial-based disease. However, two
recent studies have implicated the flexor and interosseous fin-
ger tendons [9, 10]. This is reinforced by a clinical
observational study by Stack et al. which demonstrates that
early RA-related inflammation can occur outside the joint
capsule, as evidenced by redness and oedema of the skin prior
to the onset of RA disease [11]. The involvement of these
extra-articular structures might potentially explain the pro-
drome of non-specific pain and stiffness that may precede
clinical synovitis.
Together with clinical and serological biomarkers, US-
detected subclinical inflammation and joint damage (i.e., bone
erosions) have been added as variables in risk prediction tools
for anti-cyclic citrullinated peptide (CCP)-positive individuals
Fig. 3 The potential uses of ultrasound in the rheumatoid arthritis
continuum. The figure illustrates the potential value of US in the
management of patients at different stages along the RA continuum: in
individuals at risk of RA, the detection of subclinical synovitis and
structural damage has shown to improve prediction of clinical arthritis,
thus informing risk stratification and management of these individuals.
US has also shown a promising role in the identification of patients with
undifferentiated arthritis who will develop RA, with potential
implications on early diagnosis and management of these patients
(‘window of opportunity’). In RA patients with established disease, in
clinical remission according to the clinical instrument (i.e., DAS 28), the
detection subclinical inflammation has been shown to predict progression
to structural damage and disease relapse after tapering of the treatment. In
this context, US has a promising role in guiding the management of these
patients, including treatment discontinuation, in addition to the routinely
used clinical instruments. Legend: Ab, antibodies; DAS, disease activity
score; PD, power Doppler; MSK, musculoskeletal; RA, rheumatoid
arthritis; US, ultrasound
Fig. 2 Bone erosion in the second
metacarpophalangeal joint in a
patient with rheumatoid arthritis.
Longitudinal scan. The callipers
point out a small bone erosion
(size 0.77 mm) in the metacarpal
head. Legend: asterisks, synovial
hypertrophy; et, extensor tendon;
mh, metacarpal head; p, proximal
phalanx
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at risk of RA [12, 13, 14•]. These tools enable at-risk individ-
uals to be stratified according to risk of inflammatory arthritis
(IA) development. In this way, individuals with a low risk of
progression can be reassured and monitored, whereas those
with a high risk of imminent arthritis can be identified for
closer monitoring and potential clinical trials [15].
In a cohort of anti-CCP-positive individuals with musculo-
skeletal symptoms but no clinical synovitis, the presence of
subclinical inflammation on US was strongly associated with
the development of IA, both at joint and patient level [12, 16].
The presence of intra-articular PD signal appears to be partic-
ularly predictive in these patients; those with a PD score of ≥ 2
in any joint were at significantly higher risk of progression
than those without PD (median 7.1 months vs 52.4 months,
HR = 3.7, p < 0.001). Similarly, individual joints with PD
score ≥ 2 were much more likely to develop clinical synovitis
(HR 31.3, p < 0.001). Patients with an erosion in at least one
joint were also more likely to progress to IA than individuals
without any erosions (median 7.5 months vs 50.1 months,
HR = 2.9, p < 0.001) [16]. US findings have also been shown
to be associated with IA development in another seropositive
arthralgia cohort [17]. In this cohort, 49/163 (30%) of patients
had US abnormalities in at least one joint. Although PD was
infrequently identified, US detected synovial thickening was
associated with development and timing of IA at patient level
(median 23 months vs 45 months, HR = 3.4, p < 0.01).
Pragmatically, US can also be used to confirm clinical sy-
novitis (and tenosynovitis) in at-risk individuals who are
suspected of having progressed to IA. Such patients, in the
earliest phases of clinical disease, are often difficult to assess
and the clinical findings can be subtle. Clinical trials investi-
gating arthritis prevention in individuals at-risk of RA are
increasingly stipulating US confirmation of clinical synovitis
for this reason [18].
Despite the several advantages described above, there are
some important considerations which must be borne in mind
for the optimum use of US in individuals at-risk of RA with-
out clinical synovitis. The points raised below argue for care-
ful and considerate, rather than indiscriminate, use of US in at-
risk populations.
First, the subclinical inflammation detectable by US is like-
ly to be a late feature in the development of IA, and when
present may represent a risk of imminent clinical synovitis.
Serial US assessments in a cohort of anti-CCP-positive at-risk
individuals suggest subclinical inflammation develops direct-
ly before clinical synovitis occurs [19]. The corollary is that
US may not be as informative in lower-risk individuals who
do not yet have imminent clinical arthritis. In line with this, a
recent US study of 273 first-degree relatives of RA patients
(FDRs), of whom only 8% were anti-cyclic citrullinated pep-
tide antibodies (ACPA)-positive, found no overall increase in
US synovitis in this population [20]. Likewise, in the
Amsterdam seropositive arthralgia cohort, whilst grey-scale
synovitis was associated with progression to IA, intra-
articular PD signal was infrequently identified and was not
predictive of progression to IA [17]. This contrasts with the
data from the Leeds CCP cohort, where PD signal was iden-
tified in 30% of patients and was strongly associated with
development of IA and its timing, both at patient and joint
levels [16]. The apparent disparity between the two studies
may be due to the different risk profiles of the at-risk individ-
uals. The Leeds cohort are all anti-CCP-positive and include
higher-risk subjects, many of whom had imminent IA; 57/136
(42%) developed IA at median 8.6 months. The Amsterdam
seropositive arthralgia cohort had comparatively lower-risk
subjects; not all are anti-CCP-positive and 51/163 (31%) de-
veloped IA at median 12 months. Moreover, when a previous-
ly published clinical prediction rule was applied to the
Amsterdam cohort [7], the predictive capacity of US findings
was observed to be highest in the groups with intermediate
and high risk of IA. The authors thus proposed that USmay be
of most value in these higher-risk patients rather than low-risk
individuals [17].
Second, given the now widespread availability of US in
early arthritis clinics, it is frequently used to aid diagnosis
and guide the management of patients suspected of having
IA. Algorithms to guide rheumatologists suggest US should
be used to guide management of ACPA-positive individuals
with inflammatory joint symptoms without clinical synovitis
[21]. In the absence of trial evidence, the optimum manage-
ment of these patients is not yet clear. However, in practice,
rheumatologists are already using US intuitively to guide the
management of these patients; if US synovitis is identified,
clinicians often consider starting treatment rather than moni-
toring for progression [8]. Clearly, there is a significant risk of
overtreatment with this approach as many of these symptom-
atic at-risk patients may not go on to develop clinical synovi-
tis, especially within the short term. Furthermore, if treatment
is initiated on the basis of the US findings, there may be little
consideration given to the therapeutic regimen and patients
could become committed to long-term drugs that might not
necessarily be required.
In addition, it is also not clear which joints, and indeed how
many joints, need to be imaged for optimum predictive accu-
racy. Studies in at-risk cohorts have used comprehensive US
protocols which include most or all relevant small joints [16,
17]. Although feasible in a research setting, this is time-
consuming and not practical in most clinical scenarios.
There will need to be further research in identifying the opti-
mum number and distribution of joints and tendons required
for risk prediction. Interestingly, a very recent study has dem-
onstrated that the detection of bone erosions in the classic sites
for RA damage, especially in the fifth metatarsophalangeal
joints, improves prediction of inflammatory arthritis in
CCP+ at-risk individuals [14•]. In this context, it would be
important to determine if some of the US scores which are
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routinely used in patients with established disease, such as the
US7 or US12, could provide equal diagnostic performances in
patients at risk without clinical synovitis [22, 23].
Ultrasound in the Confirmation of Diagnosis of
Rheumatoid Arthritis
The diagnosis of RA is mainly clinically based with many
clinicians relying on the fulfilment of the 2010 ACR/
EULAR classification criteria for RA [24] for reassurance.
The presence of synovitis and RA-related bone erosions are
important components of these criteria. Both these EULAR/
ACR criteria and the EULAR recommendations for the man-
agement of early RA [25] acknowledge the potential value of
additional imaging (other than X-ray), such as US, to confirm
the presence of inflammation. However, the ACR/EULAR
RA criteria state that the information gained from the US
can only be used if clinical synovitis has been confirmed in
at least one joint, making it problematic for the ‘pre-RA’
group with no clinical findings.
The value of US for the diagnosis of RA lies in its ability to
confirm the presence and extent of inflammation and its se-
quelae in addition to finding alternative explanations for
symptoms through a differential diagnosis. One of the most
common and challenging subsets of patients are those with
undifferentiated arthritis (UA), and especially those that are
seronegative. In the context of ‘treat-to-target’ (T2T) strategy,
the early identification of patients with UA who will eventu-
ally develop RA is of utmost importance to guide early and
aggressive therapy during the ‘window of opportunity’ [26].
We will highlight a number of studies that demonstrated that
US-proven joint or tendon inflammation might have an im-
portant prognostic role for persistent disease in patients with
early UA, in which a definite diagnosis cannot be reached.
Freeston et al. evaluated the value of PD signal, in combi-
nation to routine clinical management, for the prediction of
persistent arthritis in 49 patients with early inflammatory
symptoms (early morning stiffness ≥ 1 h in the hands, with
or without clinical synovitis, lasting less than 3 months) [27].
At 12 months, 47% of patients developed RA, 31% had other
IA (i.e., reactive arthritis or connective tissue disease), and
22% did not develop persistent arthritis. In the patients who
were seronegative for rheumatoid factor (RF) and anti-CCP
antibodies, but who had high C-reactive protein (CRP), swol-
len joint count, or bone erosion on conventional radiography,
the presence of grey scale (GS) or PD synovitis increased the
probability to develop persistent arthritis from 30 to 94%. In a
prospective observational study conducted on 60 patients with
new-onset UA not fulfilling the 2010 ACR/EULAR RA clas-
sification criteria, the presence of GS synovitis at baseline,
especially if higher than grade 2, was predictive of progression
to RA and methotrexate (MTX) use [28]. Such predictive
value was independent of other clinical measures, such as
the swollen joint count, or disease activity scores.
Interestingly, PD signal was not associated with any of the
outcomes evaluated (i.e., progression to RA or MTX use),
probably because of the low number of joints showing PD at
baseline. In a study by Sahbudin et al., the predictive value of
US-detected tenosynovitis and synovitis for the fulfilment the
2010 ACR/EULAR RA classification criteria was evaluated
in a cohort of 107 early arthritis patients with clinical synovitis
and symptom duration ≤ 3 months [10]. In this study, US-
detected tenosynovitis of the finger flexor tendons resulted an
independent factor for the prediction of RA, over and above
the presence of anti-CCP antibodies and synovitis on US.
Ultrasound in the Differential Diagnosis
In daily clinical practice, the clinical question that often comes
along with a request for an US exam is very simple: ‘Is there
any inflammation?’ Although this may appear a reductive
concept for using US, it is in reality extremely useful as it
allows the immediate differentiation of a potentially serious
inflammatory disease from a less serious (in joint terms) me-
chanical or degenerative process, or unspecified pain syn-
drome. It should be noted that the interpretation of any US-
detected joint inflammatory lesion should be construed in the
context of other joint findings. For example, it is acknowl-
edged that inflammation accompanies structural changes of
osteoarthritis (OA) in the hands and feet [29]. Once the diag-
nosis of synovitis (or tenosynovitis) has been established, US
may then offer a potential role in the differential diagnosis
between the different types of arthritis. In a study carried out
by Gutierrez et al., the value of US in the differential diagnosis
between RA and psoriatic arthritis (PsA) was evaluated [30];
here in 18 patients with RA and 20 patients with PsA, the
presence of peritenon finger extensor tendon inflammation
was found in 54 out 82 metacarpophalangeal (MCP) joints
in patients with PsA, and in none of the MCP joints of the
patients with RA (p < 0.001). The results of this study suggest
that the presence of inflammation on US at this specific ana-
tomical site is a higher characteristic of PsA and is potentially
useful in the differential diagnosis between RA and PsA at the
MCP joint level.
The identification of extra-capsular inflammation on US,
with or without synovitis, and peri-tendonitis of the finger
extensor tendons have also shown to have potential value for
differentiating RA from other rheumatic conditions, such as
palindromic rheumatism (PR) [31•, 32] and systemic lupus
erythematosus (SLE) [33–35]. A significant proportion of pa-
tients with PR will eventually develop RA. US evaluation of
these patients shows a high prevalence of extra-capsular in-
flammation (including tenosynovitis, peri-articular inflamma-
tion, and peri-tendonitis) during flares [31, 32], with isolated
extra-capsular inflammation a specific finding in PR [31•]. It
is conceivable that, in PR patients, reversible flares of extra-
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capsular inflammation eventually progress to persistent intra-
articular inflammation as RA develops [36]. As such, US may
be invaluable in differentiating a patient with new RA from a
patient with PR who does not have intra-articular disease.
Such distinction is often difficult on clinical grounds alone,
yet it is critically important, as the management of the two
conditions is very different.
In a small study, Ogura et al. retrospectively investigated
the US abnormalities at joint and tendon levels in the hands of
15 treatment-naïve SLE patients and 40 treatment-naïve RA
patients [34]. Interestingly, the authors found a high preva-
lence of tenosynovitis, which was higher in the SLE group
(93% versus 65% respectively, p = 0.045). Moreover, it was
shown that, differently from what it was observed in patients
with RA, the involvement of the finger extensor tendon (i.e.,
peri-tendonitis) in patients with SLE was frequently detected
in absence of joint synovitis, thus suggesting the potential role
of US in depicting different patterns of articular involvement
in these two diseases.
The accessory pulley linked to the flexor digitorum tendon
has emerged a potential specific target of the musculoskeletal
involvement in patients with PsA, especially in those with
established disease and a previous history of PsA-related
dactylitis [37]. In a recent study including 27 patients with
RA and 27 patients with PsA, Tinazzi et al. observed that
the accessory pulleys are thickened in subjects with PsA com-
pared with RA, especially in the setting of dactylitis, suggest-
ing a potential pathogenetic role of the pulley in the develop-
ment of tenosynovitis, as well as in the differential diagnosis
between PsA and RA [38]. Bone erosions have traditionally
been considered as one of the hallmarks of RA, despite not
specific for the disease. Interestingly, in a study carried out by
Zayat et al. including a total of 310 patients (70 RA, 60 PsA,
60 gout, 60 OA, and 60 healthy volunteers), US has demon-
strated the discriminative ability to differentiate RA from oth-
er diseases, when large erosions in certain target sites are eval-
uated [39]. In this study, the presence of larger erosions in
selected joints, such as the second and fifth MCP joints, the
distal ulna, and the fifth metatarsophalangeal joint, were high-
ly specific for and predictive of RA.
Clinically, it can be challenging to find firm examination
and laboratory or radiological evidence for a crystal arthropa-
thy, even though a clinical history may be suggestive. US has
recently begun to be accepted as a diagnostic tool in gout and
calcium pyrophosphate deposition disease (CPPD). In these
conditions, the spectrum of soft tissues US findings indicating
monosodium urate (MSU) or calcium pyrophosphate (CCP)
crystal deposits is broad and heterogeneous [40, 41]. Indeed,
the ‘double contour sign’, defined by the latest Outcome
Measures in Rheumatology (OMERACT) definition as ‘an
abnormal hyperechoic band over the superficial margin of
the articular hyaline cartilage, which may be either irregular
or regular, continuous, or intermittent’, is now an integral part
of the rheumatology glossary [42]. It represents the most rep-
resentative US finding in patients with gout, and it has been
included in the latest gout ACR/EULAR classification criteria
[43]. However, in patients with suspected gout, performing
the US evaluation with the only aim of identifying the ‘double
contour sign’ would be limiting, as a wide spectrum of US
findings indicating MSU microcrystal aggregates of various
size and shape (i.e., ‘hard tophi’, ‘soft tophi’, ‘uratic clouds’)
has been described both at joint and tendon levels (Fig. 4)
[44–47].
Similarly, the identification of certain US findings within
peculiar target tissues (i.e., CCP aggregates in the meniscal
and in the wrist triangular fibrocartilages, or within the artic-
ular hyaline cartilage) has demonstrated an excellent sensitiv-
ity and specificity for the diagnosis of CPPD [48–51]. In the
clinical context of suspected crystal arthropathy, the detection
of such US findings provides valuable information which
might help the rheumatologist in the differential diagnosis
decision-making process. However, the correct interpretation
of the US findings in these patients might be more insidious in
certain clinical scenarios. The high reflectivity which charac-
terizes the microcrystal aggregates might also be generated by
other pathological conditions (i.e., degenerative or mechanical
damage) and other potential pitfalls, such as the ‘fluid-carti-
lage interface’ sign, might mimic the ‘double contour sign’,
and lead to misinterpretations of the US findings in the hands
of a non-expert sonographer [41]. Care, therefore, is warranted
when reporting findings and interpreting reports.
Ultrasound in the Monitoring of Patients with
Rheumatoid Arthritis
Several studies have shown that US is able to demonstrate
changes in synovitis and tenosynovitis over time in patients
with RA. For example, in a study by Naredo et al. on 42
patients with early RA (joint symptoms < 1 year) who started
treatment with conventional disease-modifying anti-rheumat-
ic drugs (c-DMARDs), synovitis on US, defined as a combi-
nation of GS and PD signals, improved in accordance with the
clinical parameters at 12 months follow-up [52]. Similarly,
Filippucci et al. evaluated the US changes induced by therapy
with adalimumab (ADA) in the wrists of 24 patients with RA,
showing a significant improvement in both the clinical and US
findings after 12 weeks of treatment. Of note, there was a
significant reduction of PD signal at all follow-up examina-
tions (week 2, week 6, andweek 12) [53]. D’Agostino et al., in
an open-label, multicentre, single-arm study, evaluated pa-
tients with RA not responsive to MTX who received intrave-
nous abatacept for 24 weeks. At week 24, there was a signif-
icant improvement in the disease activity indices, as well as in
the US findings, as documented by the reduction of PD signal
[54].
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Other than showing changes induced by systemic treat-
ments, US has also the potential to detect changes induced
by local therapy. In a study carried out by Gutierrez et al.,
114 patients with RA and tenosynovitis were randomized
to receive either a conventional “blind” or US-guided lo-
cal injection with corticosteroids [55]. In the 60 patients
who underwent the US-guided injection, the scores of PD,
as well as the clinical measures (Health Assessment
Questionnaire and Visual Analogical Scale for global
and local pain), decreased significantly in the follow-up
(4 weeks).
Given that US is able to detect changes in inflammation
levels, which patients would most benefit from a scan, given
the limitations of resources including time and cost? At pres-
ent, we consider three scenarios:
(1) Patients with long-standing disease who develop new
symptoms. Do these relate to active disease, complica-
tions of the disease, or a new additional problem?
(2) Patients not responding to therapy. Is the primary diag-
nosis correct before we consider a switch or escalation in
therapy? For example, if US detects no features of RA,
this may allow the clinician to consider an alternative
diagnosis. The finding of no abnormalities might suggest
a chronic pain syndrome whilst the presence of
osteophytosis might suggest OA. It should be remem-
bered that the 2010 ACR/EULAR RA classification
criteria may generate false positives and from our own
data (unpublished), up to 10% of those patients called
RA by the criteria, might not actually have the disease.
(3) Patients with significant subclinical disease at baseline
which highlighted a substantial mismatch between clin-
ical and US examination. In this scenario, relying on
clinical assessment alone may underestimate inflamma-
tion load.
The Utility of Ultrasound in Rheumatoid Arthritis
Patients in Clinical Remission
Observations on Remission
In comparison to a few decades ago, the prognosis and out-
come of patients with RA have improved drastically.
Accordingly, the number of RA patients achieving clinical
remission has grown exponentially [56, 57]. This appears as
the consequence of an earlier diagnoses being made, the ap-
plication of the T2T strategy following the ACR and EULAR
recommendations, and the improvement in the therapeutic
armamentarium, with a particular regard to the advent of the
biologic (b)-DMARDs [58].
Disease activity in patients with RA is commonly assessed
using clinical instruments, such as DAS28-erythrocyte sedi-
mentation rate (ESR) or Clinical Disease Activity Index
(CDAI), both in clinical practice and in trials. These compos-
ite measures of disease activity rely on surrogate markers of
inflammation, such as tender or swollen joint count and in-
flammatory markers (i.e., ESR, CRP), with the risk of under-
or overestimating the disease activity status [59, 60].
What Is ‘True Remission’?
Several studies have demonstrated that subclinical inflamma-
tion could be found on US in RA patients which are in clinical
remission according to the clinical measures (i.e., DAS28-
ESR). Naredo et al. explored the prevalence of subclinical
synovitis on 67 RA patients in clinical remission (defined as
DAS28 < 2.6 or as Simplified Disease Activity Index (SDAI)
< 3.3)) which were treated with MTX for at least 2 years [61].
In this study, synovial hypertrophy and PD signal were found
respectively in 87.8 and 46.3% of patients in clinical remis-
sion according to DAS28, and in 81.8 and in 36.4% of patients
in clinical remission according to SDAI. Similarly, in a study
including 209 patients with established RA, the presence of
Fig. 4 “Double contour sign” and
a large bone erosion in the second
metacarpophalangeal joint in a
patient with gout. Longitudinal
scan. The US image shows the
presence of the “double contour
sign” (arrowheads) over the
hyaline cartilage, as well as the
presence of a large extra-articular
bone erosion filled with
hyperechoic spots (arrows)
indicating monosodium urate
crystal deposits. Legend: et,
extensor tendon; mh, metacarpal
head; p, proximal phalanx
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subclinical synovitis, as documented by the presence of PD
signal, was detected at both 6 and 12 months in the hands of
more than 90% of patients in clinical remission after initiation
of b-DMARDs [62]. The presence of US-detected subclinical
inflammation was found in patients with RA even when more
stringent criteria for clinical remission were used. In a study
carried out by Brown et al., including 107 RA patients in
clinical remission according not only to DAS28, but also to
ACR remission criteria and to strict definition of clinical re-
mission (no symptoms and no tender/swollen joints on clinical
examination), the prevalence of GS changes and PD signal
was very high (73 and 43%, respectively), regardless of the
criteria of remission adopted [63].
Ultrasound-Detected Subclinical Synovitis in Rheumatoid
Arthritis Patients in Clinical Remission: Is it Relevant?
The potential clinical relevance of subclinical synovitis has
been highlighted by a few studies which have shown that
some RA patients, despite being in clinical remission, do not
achieve a good functional outcome and show radiographic
progression over time, raising the hypothesis that this could
be the consequence of the persistence of such subclinical sy-
novitis [64].
In a longitudinal study, Brown et al. observed that 19% of
patients in clinical remission showed radiographic progression
at 12 months [65]. Interestingly, the authors demonstrated that
the PD scores at baseline were associated with a worse radio-
graphic outcome. Moreover, the presence of PD signal in the
MCP joints was significantly associated with radiographic
progression in any joint, including the hands and feet. In an-
other study, including 24 patients with established RA (mean
disease duration of 114.5 months) in clinical remission, the
authors documented a significant association between the
presence of subclinical inflammation on US (mainly PD sig-
nal) in a particularMCP joint and the presence of bone erosion
in that same joint, suggesting a possible link between the
presence of subclinical inflammation and the development
of bone erosions [66]. In a prospective observational study,
including 125 RA patients treated with tumour necrosis factor
alfa inhibitors in clinical remission according to DAS28, the
authors found that PD signal, especially if greater than grade 1
and near to the bone surface, was significantly associated with
radiographic progression at 12 months follow-up [67].
In a very recent prospective study, 383 patients with active
moderate to severe RA (CDAI > 10) were managed either
withUSor according to routine care and followed up for 1 year
[68]. In this study, there was no significant difference regard-
ing the clinical outcomes (i.e., CDAI or DAS28-ESR) be-
tween the two groups. However, a significant association be-
tween PD and GS synovitis at baseline and increased risk for
joint damage progression during the follow-up was detected.
These findings have raised the need of a more comprehen-
sive definition on remission, the so called ‘multidimensional
remission’, which includes the imaging (and serological) pa-
rameters, other than the commonly adopted clinical measures,
such as tender or swollen joint count and the physician visual
assessments [69]. Longitudinal studies are need to further es-
tablish the clinical utility of this new definition of remission.
Can Ultrasound Predict the Outcome of Treatment
Tapering/Discontinuation in Rheumatoid Arthritis Patients
in Clinical Remission?
Given the growing number of patients with RA achieving
clinical remission, DMARDs tapering, or even discontinua-
tion, with the aim to reduce costs and safety issues, has now
become a ‘hot topic’ and a question of paramount importance
[70]. Data from randomized controlled trials (RCTs), registry-
based, and observational studies suggest that a status of
treatment-free clinical remission is an obtainable target in
some patients with RA [71]. On the other hand, other studies
have demonstrated that a considerable number of RA patients
flare when the therapy is tapered or discontinued, with signif-
icant impact of quality of life and possible joint damage pro-
gression [72]. In this context, the identification of biomarkers,
which might help at delineating the ‘ideal’ patient for treat-
ment tapering or discontinuation, predicting the outcome of
such decision, becomes extremely important.
A few studies have demonstrated that the presence of US
subclinical synovitis in RA patients in clinical remission
might represent a predictive factor for disease flare after treat-
ment tapering/discontinuation. In a study including 42 RA in
clinical remission in which treatment with b-DMARDs was
discontinued, not the clinical measures (including DAS28),
but the presence of US subclinical inflammation at baseline
predicted disease relapse following treatment discontinuation
[73]. In a study carried out by El Miedany et al., 126 out of
157 patients with RA in clinical remission receiving c-
DMARDs and/or b-DMARDs were randomly allocated be-
tween 4 different tapering regimes, whereas 31 patients con-
tinued the full therapy dose [74]. In this study, the rates of
disease relapse were significantly associated with high base-
line US scores (both GS and PD scores).
As well as synovitis, also bone erosions have been associ-
ated with disease flare in RA patients in clinical remission in
which the treatment was tapered or discontinued. In an obser-
vational study including 44 RA patients in clinical remission
which discontinued b-DMARD therapy, bone erosions on US
were an independent prognostic factor for disease relapse
12 months after treatment discontinuation [75]. In this study,
neither the presence of US synovitis, nor the clinical or other
serological biomarkers (i.e., inflammatory markers), were as-
sociated with disease flare at follow-up.
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Can Ultrasound Help Guide Treatment in Rheumatoid
Arthritis Patients?
Despite a growing evidence supporting the potential role of
US in the monitoring of patients with RA, including those in
clinical remission, the use of US in this clinical context is still
limited. Two recent RCTs (TASER and ARTIC) have dem-
onstrated that a treatment strategy based on the US assessment
did not lead to an improved clinical outcome in comparison
with a conventional T2T approach, suggesting that the sys-
tematic use of US in the follow-up of RA patients would be
not justified [76, 77].
However, it has been suggested that the methodological
design of these studies impacts on their ability to show any
difference [78•]. For example, it may be argued that the treat-
ments offered in both arms were already optimized and thus
by adding US in was unlikely to show any additional differ-
ence. Practically, the offered treatment strategies may also be
considered more aspirational than those delivered in the real
world, and as such US might have been more likely to have
had an observed effect in real world management. It has been
postulated that if the study population consisted of patients
where there was at baseline a significant mismatch between
clinical findings and US rather than applying it to all comers,
then a difference may have found. This would have been
much more representative of how US is actually applied in
every practice.
The authors of ARTIC and TASER have clearly highlight-
ed the need for further work before US could be considered for
guiding treatment management, including DMARDs de-esca-
lation, in patients with RA [79]. A feasible and standardized
US protocol, which could potentially be integrated into a
clinical-centred monitoring strategy, is the ‘conditio sine qua
non’ to improve the reliability and clinical usefulness of US in
the follow-up of patients with RA. To date, how many joints
(and which joints) should be included, which pathological
findings should be taken into account, how the US assessment
should be carried out (dorsal, lateral, or volar scan), and how
to score the US images remain important open questions.
Moreover, more efforts are needed to overcome the intrin-
sic and well-known limitations of US, such as the high
operator-dependence and the consequent large inter-operator
variability. Finally, further longitudinal studies are necessary
to validate the possible predictive role of the US findings (i.e.,
subclinical inflammation or bone erosions) for successful (or
unsuccessful) DMARDs tapering or discontinuation in RA
patients in clinical remission.
Conclusions
This review has highlighted the current and potential utility of
US imaging across the RA continuum. Its ability to identify
early inflammatory and structural changes in joints and soft
tissues has clear benefits for early diagnosis and prediction of
outcome through risk stratification and ensuring optimal dis-
ease control. As technology improves, US is allowing new
insights into understanding joint pathology as well as helping
differentiation between diseases. As with all research, as more
data is produced, more questions are being asked. More ap-
propriately designed RCTs are required to identify which
groups of patients benefit the most from US imaging.
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